---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-036816"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:25:51.340956+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Catalyst Pharma reports FY2024 revenue $491.7M (+23.5% YoY), guides FY2025 $545-565M

## Summary
- Q4 net product revenue $141.8M; full-year FIRDAPSE revenue $306M (+18.4%), AGAMREE $46M (new launch).
- GAAP net income $163.9M ($1.31 diluted EPS) vs $71.4M ($0.63) in 2023; non-GAAP net income $276.3M ($2.21 diluted EPS).
- Cash and equivalents $517.6M at year-end, up 276% from $137.6M a year ago.
- Full year 2025 revenue guidance set at $545-565M, reflecting continued growth momentum.

## SEC filing metadata
- accession: 0001193125-25-036816
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312525036816/0001193125-25-036816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312525036816/d861503d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-036816
- JSON: https://secwatch.observer/filing/0001193125-25-036816.json
- Plain text: https://secwatch.observer/filing/0001193125-25-036816.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.